Strides Receives US FDA EIR for Flagship Facility in Bengaluru
Strides receives the US Food and Drug Administration (FDA) Establishment Inspection Report (EIR) for its flagship Bengaluru facility following a current Good Manufacturing Practice (cGMP) inspection conducted in May 2026.
CGMP Inspection | 20/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy